Report Sections

See All Reports

  • HP:0011123: Inflammatory abnormality of the skin
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0011123: Inflammatory abnormality of the skin

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (5)


    Name (Synonyms) Correlation
    drug1692 Hand sanitizer and hand washing Wiki 0.50
    drug817 CYP 450 Substrates Wiki 0.50
    drug146 ATI-1777 Wiki 0.50
    Name (Synonyms) Correlation
    drug2526 Nemolizumab Wiki 0.50
    drug4202 Vehicle Wiki 0.50

    Correlated MeSH Terms (4)


    Name (Synonyms) Correlation
    D003872 Dermatitis NIH 1.00
    D003876 Dermatitis, Atopic NIH 0.87
    D004485 Eczema NIH 0.87
    Name (Synonyms) Correlation
    D012868 Skin Abnormalities NIH 0.50

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0000964 Eczema HPO 0.87
    HP:0001047 Atopic dermatitis HPO 0.87
    HP:0000951 Abnormality of the skin HPO 0.35

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Re-opening of the Country and Dermal Consequences of Mandatory Intensified Handwash and Hand Disinfection Among a Danish Pediatric Population During the COVID19 Pandemic

    During the COVID-19 pandemic after reopening of the country, school, kindergarten and daycare, children have been obligated to do frequent handwash. The study group wished to investigate whether this has had implications on symptoms of dry, red, itchy or sore hands and hand eczema. The investigation was performed within the first and second week after reopening by questionnaires distributed to parents electronically via schools, kindergartens and daycare facilities electronic platforms.

    NCT04375410
    Conditions
    1. Hand Eczema
    2. Hand Dermatitis
    3. Covid19
    MeSH:Dermatitis
    HPO:Inflammatory abnormality of the skin

    Primary Outcomes

    Description: Dermal symptoms as a result of frequent hand wash and disinfection among children

    Measure: Dermal reaction to frequent hand wash and disinfection in children

    Time: 9 days
    2 Hand Sanitizer Effects on the Skin Barrier

    Hand washing and the use of hand sanitizers are important interventions in disease prevention. Engaging in frequent hand washing is especially effective in preventing the spread of viruses, as this removes microbes and prevents the spread to others. Hand dermatitis, however, is a common occurrence in certain occupations, such as healthcare workers. With the onset of the SARS-CoV2 (COVID-19) pandemic, hand hygiene measures are further enforced as there is no cure or vaccine for this virus. In the study, the effects of hand washing and the use of hand sanitizer on skin proteins and lipids will be assessed.

    NCT04525521
    Conditions
    1. Dermatitis Hand
    2. Skin Abnormalities
    3. Atopic Dermatitis
    4. Atopic Dermatitis Eczema
    Interventions
    1. Other: Hand sanitizer and hand washing
    MeSH:Dermatitis, Atopic Skin Abnormalities Dermatitis Eczema
    HPO:Abnormality of the skin Atopic dermatitis Eczema Eczematoid dermatitis Inflammatory abnormality of the skin

    Primary Outcomes

    Description: Skin barrier assessments at baseline, then after hand sanitizer use will be performed. Analysis of skin filaggrin breakdown products, lipid profiles, and transepidermal water loss will be compared.

    Measure: Measure the change in transepidermal water loss and skin components after using hand sanitizer.

    Time: Through study completion, up to 1 year

    Description: Skin barrier assessments after hand washing with soap and water will be performed. Analysis of skin filaggrin breakdown products, lipid profiles, and transepidermal water loss will be compared.

    Measure: Measure the change in transepidermal water loss and skin components after hand washing with soap and water.

    Time: Through study completion, up to 1 year

    Secondary Outcomes

    Description: Questionnaires will capture symptoms of hand dryness, frequency of hand washing, and other environmental exposures. This data will be compared to the degree of transepidermal water loss and skin barrier findings.

    Measure: Individual reporting of hand dryness and environmental exposures

    Time: Through study completion, up to 1 year
    3 An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects With Moderate-to-Severe Atopic Dermatitis

    The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in adult participants with moderateto- severe atopic dermatitis (AD).

    NCT04562116
    Conditions
    1. Atopic Dermatitis
    Interventions
    1. Drug: Nemolizumab
    2. Drug: CYP 450 Substrates
    MeSH:Dermatitis, Atopic Dermatitis Eczema
    HPO:Atopic dermatitis Eczema Eczematoid dermatitis Inflammatory abnormality of the skin

    Primary Outcomes

    Description: Change of AUC (0-infinity) of each of the 5 probe drugs before and after 9-week nemolizumab treatment will be assessed. AUC (0-infinity) is defined as AUC from time 0 to infinity, calculated as the sum of AUC (0-last) and C(last)/lambda(z); where C(last) is the last observed measurable (non-BQL) concentration; and lambda(z) is apparent terminal elimination rate constant.

    Measure: Change of Area Under the Concentration-time Curve from Time Zero to Infinity (AUC[0-infinity]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    Time: Baseline (Week 0) and Week 10: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose'

    Description: Change of AUC (0-last) of each of the 5 probe drugs before and after 9-week nemolizumab treatment will be assessed. AUC (0-last) is defined as AUC from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) concentration, calculated by linear-linear trapezoidal summation.

    Measure: Change of Area Under the Concentration-time Curve from Time Zero to the Time of the Last Measurable Concentration (AUC [0-last]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    Time: Baseline (Week 0) and Week 10: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose'

    Description: Change of Cmax of each of the 5 probe drugs before and after 9-week nemolizumab treatment will be assessed. Cmax is defined as the maximum observed plasma concentration.

    Measure: Maximum Observed Plasma Concentration (Cmax) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment

    Time: Baseline (Week 0) and Week 10: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 72 and 120 hours post-dose'

    Secondary Outcomes

    Description: Incidence of AEs including treatment emergent AEs (TEAEs), AEs of special interest (AESIs), and serious AEs (SAEs) will be reported. An AE is defined as any untoward medical occurrence in a study participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. A TEAE is defined as an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.

    Measure: Incidence of Adverse Events (AEs)

    Time: Up to 24 weeks

    Description: The severity of AEs including TEAEs, AESIs, and SAEs will be assessed as mild, moderate or severe.

    Measure: Severity of Adverse Events (AEs)

    Time: Up to 24 weeks
    4 A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

    This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of patients with moderate or severe atopic dermatitis.

    NCT04598269
    Conditions
    1. Atopic Dermatitis
    Interventions
    1. Drug: ATI-1777
    2. Drug: Vehicle
    MeSH:Dermatitis, Atopic Dermatitis Eczema
    HPO:Atopic dermatitis Eczema Eczematoid dermatitis Inflammatory abnormality of the skin

    Primary Outcomes

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Percent change from baseline in EASI score at Day 28

    Time: Baseline to Day 28

    Secondary Outcomes

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Percent change from baseline in EASI score at Day 8

    Time: Baseline to Day 8

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Percent change from baseline in EASI score at Day 15

    Time: Baseline to Day 15

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Proportion of patients who achieve 50% improvement in EASI score (EASI 50) within 28 days of the start of treatment

    Time: Day 28

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Proportion of patients who achieve 75% improvement in EASI score (EASI-75) within 4 weeks of the start of treatment

    Time: Baseline to Day 28

    Description: EASI = Eczema Area and Severity Index. The EASI evaluation is performed by the Principal Investigator and will evaluate Atopic Dermatitis in each of 3 body regions (trunk [excluding groin and genitalia], upper extremities [excluding palms of hands], and lower extremities [excluding soles of feet]). The EASI scoring system uses a defined process to grade the severity of the signs of AD and the extent affected. EASI Scores range from 0-72, with higher score indicative of more severe disease.

    Measure: Proportions of patients who achieve 90% improvement in EASI score (EASI-90) within 4 weeks of the start of treatment

    Time: Baseline to Day 28

    Description: IGA = Validated Investigator Global Assessment scale for Atopic Dermatitis. The IGA is the investigator's assessment of the average overall severity of patient's AD at a particular point in time. Scores range from 0-4, with higher scores indicative of more severe disease.

    Measure: Change from baseline in IGA score at Day 8

    Time: Baseline to Day 8

    Description: IGA = Validated Investigator Global Assessment scale for Atopic Dermatitis. The IGA is the investigator's assessment of the average overall severity of patient's AD at a particular point in time. Scores range from 0-4, with higher scores indicative of more severe disease.

    Measure: Change from baseline in IGA score at Day 15

    Time: Baseline to Day 15

    Description: IGA = Validated Investigator Global Assessment scale for Atopic Dermatitis. The IGA is the investigator's assessment of the average overall severity of patient's AD at a particular point in time. Scores range from 0-4, with higher score indicative of more severe disease. 0-100%, with higher score indicative of increased percentage of atopic dermatitis on the skin.

    Measure: Change from baseline in IGA score at Day 28

    Time: Baseline to Day 28

    Description: BSA = Percent of Body Surface Area of Atopic Dermatitis. The total percentage of the patient's BSA affected by AD will be estimated by the investigator or designee using the handprint method, which estimates that the area of a patient's full handprint (fingers and thumbs together) constitutes 1% of their total BSA. Scores range from 0-100%, with higher score indicative of increased percentage of atopic dermatitis on the skin.

    Measure: Change from baseline in BSA at Day 8

    Time: Baseline to Day 8

    Description: BSA = Percent of Body Surface Area of Atopic Dermatitis. The total percentage of the patient's BSA affected by AD will be estimated by the investigator or designee using the handprint method, which estimates that the area of a patient's full handprint (fingers and thumbs together) constitutes 1% of their total BSA. Scores range from 0-100%, with higher score indicative of increased percentage of atopic dermatitis on the skin.

    Measure: Change from baseline in BSA at Day 15

    Time: Baseline to Day 15

    Description: BSA = Percent of Body Surface Area of Atopic Dermatitis. The total percentage of the patient's BSA affected by AD will be estimated by the investigator or designee using the handprint method, which estimates that the area of a patient's full handprint (fingers and thumbs together) constitutes 1% of their total BSA. Scores range from 0-100%, with higher score indicative of increased percentage of atopic dermatitis on the skin.

    Measure: Change from baseline in BSA at Day 28

    Time: Baseline to Day 28

    Description: PP-NRS = Peak Pruritus Numerical Rating Scale. The PP-NRS is a single patient-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours. Scores range from 0-10, with higher scores indicative of more severe itching.

    Measure: Change from baseline in PP-NRS score at Day 8

    Time: Baseline to Day 8

    Description: PP-NRS = Peak Pruritus Numerical Rating Scale. The PP-NRS is a single patient-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours. Scores range from 0-10, with higher scores indicative of more severe itching.

    Measure: Change from baseline in PP-NRS at Day 15

    Time: Baseline to Day 15

    Description: PP-NRS = Peak Pruritus Numerical Rating Scale. The PP-NRS is a single patient-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours. Scores range from 0-10, with higher scores indicative of more severe itching.

    Measure: Change from baseline in PP-NRS score at Day 28

    Time: Baseline to Day 28

    Other Outcomes

    Description: Laboratory measure will be categorized as normal, high, or low. Normal laboratory values represent better outcomes. Laboratory measures include White Blood Cell (WBC) Count, Absolute Neutrophil Count (ANC), Aspartate Aminotransferase, Lymphocyte count, Platelet count, Hemoglobin, and Serum creatinine. The status at the final value at the end of the treatment period will be compared with that at the study baseline and the "shifts" from study baseline will be summarized using the number and percentage of patients in each shift category by treatment group.

    Measure: Proportion of Subjects Experiencing a Shift from Baseline Laboratory Values

    Time: Baseline to Day 28

    Description: Laboratory measure will be summarized using descriptive statistics for numeric variables and numbers and percentages for categorical variables at each scheduled assessment. Numeric hematology, chemistry, and urinalysis results will be summarized using change from baseline as well.

    Measure: Summary of Hematology at Day 28

    Time: Baseline to Day 28

    Description: Laboratory measure will be summarized using descriptive statistics for numeric variables and numbers and percentages for categorical variables at each scheduled assessment. Numeric hematology, chemistry, and urinalysis results will be summarized using change from baseline as well.

    Measure: Summary of Serum Chemistry at Day 28

    Time: Baseline to Day 28

    Description: Laboratory measure will be summarized using descriptive statistics for numeric variables and numbers and percentages for categorical variables at each scheduled assessment. Numeric hematology, chemistry, and urinalysis results will be summarized using change from baseline as well.

    Measure: Summary of Urinalysis at Day 28

    Time: Baseline to Day 28

    Description: Vital signs will be presented descriptively. Vital signs will be measured in a semi-supine position after 5 minutes of rest and will include temperature, systolic and diastolic blood pressure, pulse, and respiratory rate.

    Measure: Summary of Abnormal Vital Signs at Day 8

    Time: Baseline to Day 8

    Description: Vital signs will be presented descriptively. Vital signs will be measured in a semi-supine position after 5 minutes of rest and will include temperature, systolic and diastolic blood pressure, pulse, and respiratory rate.

    Measure: Summary of Abnormal Vital Signs at Day 15

    Time: Baseline to Day 15

    Description: Vital signs will be presented descriptively. Vital signs will be measured in a semi-supine position after 5 minutes of rest and will include temperature, systolic and diastolic blood pressure, pulse, and respiratory rate.

    Measure: Summary of Abnormal Vital Signs at Day 28

    Time: Baseline to Day 28

    Description: ECG = Electrocardiogram. Clinically significant ECG findings include, but not limited to, ectopic atrial rhythm, clinically significant conduction disturbance including PR >240 msec, pre-excitation (delta wave and PR < 120 msec), second degree or higher atrioventricular block, new finding of QRS > 120 ms, evidence of of QT-interval prolongation, and acute signs of ischemia or infarction.

    Measure: Summary of Abnormal Physical 12-lead ECG reading at Day 28

    Time: Baseline to Day 28

    HPO Nodes


    HP:0011123: Inflammatory abnormality of the skin
    Genes 494
    ALOXE3 CARD11 LPIN2 COL7A1 RNASEH2C NLRP3 LSS VEGFC PGM3 EDA ECM1 FECH NFKB2 LHCGR COL7A1 CD247 FCGR2B SDHC GJB2 GP1BB LAMA3 KRT1 KIF11 SH3PXD2B CLEC7A IL2RG TARS1 EXTL3 MCCC2 SEC24C FLG NLRP3 STING1 EGFR PIGA TNFRSF1A CYBB HLA-DPB1 KRT10 ABCA12 HLA-C CDK10 ABCA12 IL17F CDH23 IKBKG GJB6 BTD IL17RA GTF2E2 FOXC2 PRF1 IL17RA JMJD1C UFD1 AGA CTLA4 ADA RAG1 TGM1 CARMIL2 PSTPIP1 LYST BTD POLE ERCC2 WAS CYBA SPINK5 CTLA4 HLA-DRB1 LMBRD1 LIPN TRAF6 RNU4ATAC IGHM TBX1 CD79A CCBE1 IL7 NIPAL4 PTPN22 SMARCA2 KRT14 LYST TKT HLA-B PNPLA1 GINS1 SMARCAD1 BTK ZNF341 SCNN1A IL7R EPG5 MS4A2 PIK3CD KRT5 BRAF NCF1 PSMB8 CD28 FCGR2A RAC1 ERCC4 MNX1 KRT10 UROS DSE AIP DDX41 KIT AP1B1 SBDS BLM GJB2 RBCK1 AIRE TNFAIP3 FOXP3 MEFV MSN IL6R CIITA CHST14 TEK MPDU1 ABCC6 GJA1 DNASE1 PRKACA RAG2 HLCS EDARADD HPGD IFIH1 ZAP70 ALOX12B NOD2 RFXANK ESR1 GJB4 H6PD MBTPS2 HYOU1 HPGD MBTPS2 EGFR LACC1 ELANE PSMB9 TBCK PGM3 IL7R HLA-DQB1 UBAC2 FLI1 TCIRG1 MYD88 LBR LMBRD1 POMP RBP4 KIT CYP4F22 HLA-B SPINK5 FAT4 ESR1 MORC2 RAG1 RNASEH2C RBM8A GTF2H5 AUTS2 PAH SPTA1 FLT4 SHOC2 NFKB2 PEPD MYD88 MIF RFX5 CYBC1 CYP4F22 CCBE1 PSMB4 IRAK1 JAK3 LIG4 POLR3A TMC6 TGM5 FGFR2 ERAP1 TNFRSF1B CSTA PRMT7 RAG2 CTLA4 EFL1 CIITA MYSM1 PRTN3 BTK GATA1 RNASEH2B DCLRE1C ZAP70 ANK1 TRPM4 BTNL2 FOXP3 KNSTRN PEPD HSPA9 KRT1 TCF3 IL12A NOD2 SCNN1G ACADVL SAMHD1 DNAJC21 MRTFA WNT4 WNT4 ADA CASR IVNS1ABP NSUN2 LPIN2 RRAS2 IL36RN EPB42 CHST14 IL23R HLA-DPA1 PSEN1 SRP54 TP63 ABCA12 IL10RA PTPN22 DOCK8 HPGD FERMT3 SDHA TMC8 LYZ DCLRE1C RIPK1 KRT5 LIG4 CARD14 AK2 BTNL2 HSD3B2 B2M KLRC4 DNAJC21 IL12A-AS1 SAMHD1 IL2RG PCCA KRT1 CD3G CTSC SIK3 SLC39A4 STAT1 JAK1 USP8 STAT5B NLRP12 ITGB4 RTTN MBL2 NIPAL4 SLC30A2 CHD7 MVK STAT4 SULT2B1 RREB1 SDR9C7 CFI ARVCF SH3PXD2B PDGFRA KRT10 TBX1 NCF4 FERMT1 RFXAP KRT1 NCF2 CD28 DOCK8 LAMC2 ADAR CARD14 TRAF3IP2 IL6 CLEC7A BCL11B CTLA4 NCF1 CD3D ERCC2 ERCC5 DNASE1L3 WAS IL4R SPP1 SPTB IL17F IL6ST STAT3 PNPLA1 LRRC8A SHANK3 IRF2BP2 ALOXE3 PLA2G7 IL17RC LBR ERCC3 IGLL1 CD79B NCF4 KDSR SRD5A3 MTHFD1 PIK3CA BLNK GJC2 NFE2L2 MYSM1 HLA-DRB1 SLCO2A1 RAG2 XIAP CYBB CERS3 NLRP3 MPLKIP CD3E NSMCE3 IL10 TTC7A NLRC4 SLC4A1 TP63 HLCS NAXD NSUN2 KRT17 CASP8 GJB2 AIRE ITGA6 TRAF3IP2 HDAC4 IFIH1 DHCR7 NCF2 RFXANK IL2RA IL2RG MEFV STAT3 CYBC1 WDR1 FGA SMARCC2 TREX1 TTC7A GJB3 ADAM17 BTK WIPF1 GNA11 SUOX STAT3 RNASEH2A COMT TBX1 RFX5 NCSTN C5 DCLRE1C ENPP1 MEFV IL10RB MVK CTSB TGM1 FAS KDF1 LAMB3 APOA1 SLC6A19 ZNF750 PAH ERCC2 ADAMTS3 FLI1 IL1RN RAC1 NOD2 STAT4 SLC29A3 ADA2 TAF1 MBTPS2 LACC1 GATA3 DSG1 AP1S3 ALOX12B EDAR SP110 EBP CYBA TNFRSF1B KRT9 ACP5 TGM1 TLR4 MEIS2 TFRC CARD9 FAM111B PAPSS2 CIB1 NFKB1 NEK9 TREX1 IFNG ELANE POR TNFRSF1A FECH FOXP1 SMARCA2 RFXAP SRP54 C4A UBE2A PSENEN RAG1 TREX1 KANSL1 MMP1 CACNA1G KRT16 PCCB NR3C1 ERCC3 MSMO1 RMRP WAS PTPRC PSTPIP1 SCNN1B KDF1 GFI1 RNF113A ADAM17 CCR1 COX4I2 HIRA PIK3R1 LIG4 IL7R XYLT1 GPR101 GTF2H5 NIPAL4 TGFB1 WIPF1 CASP10 SDHB CTLA4 GJC2 RNU4ATAC TGM1 CTSC HLA-DRB1 FOXN1 STAT1 KIT
    Protein Mutations 4
    G2545R H2507Q T454A V66M
    SNP 1
    rs6265

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0011123: Inflammatory abnormality of the skin
    Genes 494
    ALOXE3 CARD11 LPIN2 COL7A1 RNASEH2C NLRP3 LSS VEGFC PGM3 EDA ECM1 FECH NFKB2 LHCGR COL7A1 CD247 FCGR2B SDHC GJB2 GP1BB LAMA3 KRT1 KIF11 SH3PXD2B CLEC7A IL2RG TARS1 EXTL3 MCCC2 SEC24C FLG NLRP3 STING1 EGFR PIGA TNFRSF1A CYBB HLA-DPB1 KRT10 ABCA12 HLA-C CDK10 ABCA12 IL17F CDH23 IKBKG GJB6 BTD IL17RA GTF2E2 FOXC2 PRF1 IL17RA JMJD1C UFD1 AGA CTLA4 ADA RAG1 TGM1 CARMIL2 PSTPIP1 LYST BTD POLE ERCC2 WAS CYBA SPINK5 CTLA4 HLA-DRB1 LMBRD1 LIPN TRAF6 RNU4ATAC IGHM TBX1 CD79A CCBE1 IL7 NIPAL4 PTPN22 SMARCA2 KRT14 LYST TKT HLA-B PNPLA1 GINS1 SMARCAD1 BTK ZNF341 SCNN1A IL7R EPG5 MS4A2 PIK3CD KRT5 BRAF NCF1 PSMB8 CD28 FCGR2A RAC1 ERCC4 MNX1 KRT10 UROS DSE AIP DDX41 KIT AP1B1 SBDS BLM GJB2 RBCK1 AIRE TNFAIP3 FOXP3 MEFV MSN IL6R CIITA CHST14 TEK MPDU1 ABCC6 GJA1 DNASE1 PRKACA RAG2 HLCS EDARADD HPGD IFIH1 ZAP70 ALOX12B NOD2 RFXANK ESR1 GJB4 H6PD MBTPS2 HYOU1 HPGD MBTPS2 EGFR LACC1 ELANE PSMB9 TBCK PGM3 IL7R HLA-DQB1 UBAC2 FLI1 TCIRG1 MYD88 LBR LMBRD1 POMP RBP4 KIT CYP4F22 HLA-B SPINK5 FAT4 ESR1 MORC2 RAG1 RNASEH2C RBM8A GTF2H5 AUTS2 PAH SPTA1 FLT4 SHOC2 NFKB2 PEPD MYD88 MIF RFX5 CYBC1 CYP4F22 CCBE1 PSMB4 IRAK1 JAK3 LIG4 POLR3A TMC6 TGM5 FGFR2 ERAP1 TNFRSF1B CSTA PRMT7 RAG2 CTLA4 EFL1 CIITA MYSM1 PRTN3 BTK GATA1 RNASEH2B DCLRE1C ZAP70 ANK1 TRPM4 BTNL2 FOXP3 KNSTRN PEPD HSPA9 KRT1 TCF3 IL12A NOD2 SCNN1G ACADVL SAMHD1 DNAJC21 MRTFA WNT4 WNT4 ADA CASR IVNS1ABP NSUN2 LPIN2 RRAS2 IL36RN EPB42 CHST14 IL23R HLA-DPA1 PSEN1 SRP54 TP63 ABCA12 IL10RA PTPN22 DOCK8 HPGD FERMT3 SDHA TMC8 LYZ DCLRE1C RIPK1 KRT5 LIG4 CARD14 AK2 BTNL2 HSD3B2 B2M KLRC4 DNAJC21 IL12A-AS1 SAMHD1 IL2RG PCCA KRT1 CD3G CTSC SIK3 SLC39A4 STAT1 JAK1 USP8 STAT5B NLRP12 ITGB4 RTTN MBL2 NIPAL4 SLC30A2 CHD7 MVK STAT4 SULT2B1 RREB1 SDR9C7 CFI ARVCF SH3PXD2B PDGFRA KRT10 TBX1 NCF4 FERMT1 RFXAP KRT1 NCF2 CD28 DOCK8 LAMC2 ADAR CARD14 TRAF3IP2 IL6 CLEC7A BCL11B CTLA4 NCF1 CD3D ERCC2 ERCC5 DNASE1L3 WAS IL4R SPP1 SPTB IL17F IL6ST STAT3 PNPLA1 LRRC8A SHANK3 IRF2BP2 ALOXE3 PLA2G7 IL17RC LBR ERCC3 IGLL1 CD79B NCF4 KDSR SRD5A3 MTHFD1 PIK3CA BLNK GJC2 NFE2L2 MYSM1 HLA-DRB1 SLCO2A1 RAG2 XIAP CYBB CERS3 NLRP3 MPLKIP CD3E NSMCE3 IL10 TTC7A NLRC4 SLC4A1 TP63 HLCS NAXD NSUN2 KRT17 CASP8 GJB2 AIRE ITGA6 TRAF3IP2 HDAC4 IFIH1 DHCR7 NCF2 RFXANK IL2RA IL2RG MEFV STAT3 CYBC1 WDR1 FGA SMARCC2 TREX1 TTC7A GJB3 ADAM17 BTK WIPF1 GNA11 SUOX STAT3 RNASEH2A COMT TBX1 RFX5 NCSTN C5 DCLRE1C ENPP1 MEFV IL10RB MVK CTSB TGM1 FAS KDF1 LAMB3 APOA1 SLC6A19 ZNF750 PAH ERCC2 ADAMTS3 FLI1 IL1RN RAC1 NOD2 STAT4 SLC29A3 ADA2 TAF1 MBTPS2 LACC1 GATA3 DSG1 AP1S3 ALOX12B EDAR SP110 EBP CYBA TNFRSF1B KRT9 ACP5 TGM1 TLR4 MEIS2 TFRC CARD9 FAM111B PAPSS2 CIB1 NFKB1 NEK9 TREX1 IFNG ELANE POR TNFRSF1A FECH FOXP1 SMARCA2 RFXAP SRP54 C4A UBE2A PSENEN RAG1 TREX1 KANSL1 MMP1 CACNA1G KRT16 PCCB NR3C1 ERCC3 MSMO1 RMRP WAS PTPRC PSTPIP1 SCNN1B KDF1 GFI1 RNF113A ADAM17 CCR1 COX4I2 HIRA PIK3R1 LIG4 IL7R XYLT1 GPR101 GTF2H5 NIPAL4 TGFB1 WIPF1 CASP10 SDHB CTLA4 GJC2 RNU4ATAC TGM1 CTSC HLA-DRB1 FOXN1 STAT1 KIT
    Protein Mutations 4
    G2545R H2507Q T454A V66M
    SNP 1
    rs6265

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook